ADC Therapeutics (ADCT) Payables (2019 - 2026)

ADC Therapeutics (ADCT) has reported Payables for 8 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.

• Quarterly Payables fell 66.04% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 66.04% YoY) and the FY2025 annual result came in at $9.2 million, down 49.11% from the prior year.
• Payables eased to $5.3 million in Q1 2026 per ADCT's latest filing, from $9.2 million in the prior quarter.
• Over the last five years, Payables for ADCT reached as high as $25.6 million in Q2 2023 and fell as low as $5.3 million in Q1 2026.
• A 5-year average of $15.9 million and a median of $15.6 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables surged 105.5% — and 2026, when it slumped 66.04%.
• Year by year, Payables stood at $24.8 million in 2022, then plunged by 37.28% to $15.6 million in 2023, then climbed by 15.8% to $18.0 million in 2024, then plunged by 49.11% to $9.2 million in 2025, then sank by 42.29% to $5.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $5.3 million, $9.2 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.